AT2 Receptors in the RVLM: Regulation of Sympathetic Outflow in Heart Failure
RVLM 中的 AT2 受体:心力衰竭中交感神经流出的调节
基本信息
- 批准号:8242721
- 负责人:
- 金额:$ 34.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-04-15 至 2015-03-31
- 项目状态:已结题
- 来源:
- 关键词:AGTR2 geneAcuteAddressAgonistAngiotensin IIAngiotensinsAnimal ModelAnimalsAreaAttenuatedBlood PressureBody WeightBrainBrain StemCGP-42112CardiacCardiovascular PhysiologyCell NucleusCellsCharacteristicsChronicConsciousConsensusCyclic GMPDataDiabetes MellitusDiseaseDoseDown-RegulationEquilibriumExcretory functionExhibitsFrequenciesGene ExpressionGene TransferGoalsHeart RateHeart failureHyperactive behaviorHypertensionIn VitroIncidenceKidneyLabelLeadLinkLiteratureMeasuresMediatingMembraneMembrane PotentialsModelingMorbidity - disease rateMyocardialNerveNeuronsNorepinephrineOutcomeOxygen ConsumptionPathway interactionsPerfusionPeripheralPhospholipase A2PhysiologicalPlayPotassiumPotassium ChannelPreparationProtein Phosphatase 2A Regulatory Subunit PR53PublishingRattusReagentReceptor GeneReceptor SignalingReceptor, Angiotensin, Type 1RegulationRenin-Angiotensin SystemReporter GenesReportingResearchRoleSeriesSignal PathwaySignal TransductionSliceSudden DeathSyndromeTestingTextTherapeuticTransfectionType 2 Angiotensin II ReceptorUnited StatesUp-RegulationUrineViralViral VectorVirusWater consumptionWorkbaseextracellularfluoroformhemodynamicsin vivoinhibitor/antagonistinsightmature animalmortalityneuronal excitabilityoverexpressionpatch clampprognosticprotein expressionreceptorreceptor densityreceptor expressionresearch studyresponserestorationtherapeutic targettreatment strategyvector
项目摘要
ABSTRACT
Chronic heart failure (CHF) is a leading cause of morbidity and mortality in the United States with the
characteristics of sympathetic overactivity and activation of the renin-angiotensin system. These are the
primary therapeutic targets for this syndrome. In this project, we propose three aims to explore the potential
benefit of over expressing angiotensin type 2 receptor (AT2R) expression in the rostral ventrolateral medulla
(RVLM) in rats with CHF. Moreover we will also determine the underlying mechanisms involved in the
sympatho-inhibitory effects of AT2R overexpression in the RVLM. It has been firmly established that, in
contrast to the influences of the AT1R, the AT2R facilitates the neuronal potassium channel and current,
which hyperpolarizes membrane potential and suppresses neuronal excitability. On the other hand, our
preliminary experiments show a down regulation of AT2R protein expression in the RVLM of rats with CHF.
These phenomena lead us to postulate that a decrease in AT2R signaling in the RVLM contributes to
sympatho-excitation of this syndrome by elevating the excitability of presympathetic neurons. Our global
hypothesis in this proposal is that over expression of the AT2R in the RVLM by gene transfer will
reduce or normalize sympathetic activation in CHF, and therefore benefit this syndrome. In
preliminary experiments, we have successfully produced a rat model in which the AT2R is selectively over
expressed in the RVLM by direct delivery of AT2R viral vectors into this area. Employing this animal model,
we will test our hypothesis by pursuing the following 3 Specific Aims. AIM 1: To determine the
hemodynamic, cardiac function, and sympathetic outflow in normal and CHF rats with
overexpression of AT2R in the RVLM. This Aim includes two components. First, we will determine the
chronic effects of over expressing AT2R in the RVLM on arterial blood pressure (AP), heart rate (HR),
cardiac function, and norepinephrine excretion in conscious normal and CHF rats. In addition, water intake,
urine excretion, and body weight will be measured. Second, we will observe the acute effects of
microinjecting agonists and antagonists of AT1R and AT2R into the RVLM with AT2R over expression on
AP, HR, and renal sympathetic nerve activity (RSNA). We will also explore the involvement of intracellular
AR2R signaling sympatho-inhibition. This includes the NO/cGMP and PLA2/AA/12-LO/PP2A pathways. AIM
2: To determine the effects of overexpressing AT2R on single presympathetic neuronal activity in
the RVLM of anesthetized rats. We will directly record extracellular single unit firing of RVLM
presympathetic neurons following overexpression of AT2R. AIM 3: To determine the effects of
overexpressing AT2R on potassium current of presympathetic neurons in the RVLM. Employing
patch clamp and brainstem slice preparations, we will directly record potassium currents of presympathetic
neurons following overexpression of AT2R. These studies will lead to an enhanced understanding of
angiotensin signaling in presympathetic neurons in the setting of CHF. They will highlight the importance of
a balance between AT1 and AT2 receptor signaling in setting the level of sympatho-excitation and identify
possible new targets for therapy in CHF.
摘要
慢性心力衰竭(CHF)是美国发病率和死亡率的主要原因,
交感神经过度活动和肾素-血管紧张素系统激活的特点。这些是
这种综合征的主要治疗目标。在这个项目中,我们提出了三个开发潜力的目标
延髓吻侧腹外侧区血管紧张素2型受体(AT2R)过度表达的益处
(RVLM)对CHF大鼠的影响。此外,我们还将确定
RVLM中AT2R过度表达的交感神经抑制作用已经确凿地证明,在
与AT1R的影响相比,AT2R促进了神经元的钾通道和电流,
它超极化膜电位并抑制神经元的兴奋性。另一方面,我们的
初步实验表明,心力衰竭大鼠RVLM中AT2R蛋白表达下调。
这些现象使我们假设RVLM中AT2R信号的减少有助于
交感神经兴奋通过提高交感前神经元的兴奋性而引起的这种综合征。我们的全球
该方案中的假设是,通过基因转移在RVLM中过度表达AT2R将
减少或正常化CHF的交感神经激活,从而有益于这一综合征。在……里面
初步实验,我们已经成功地建立了一种AT2R选择性终止的大鼠模型
通过将AT2R病毒载体直接输送到该区域,在RVLM中表达。利用这种动物模型,
我们将通过追求以下三个具体目标来检验我们的假设。目标1:确定
正常和慢性心力衰竭大鼠的血流动力学、心功能和交感神经流出
AT2R在RVLM中的过度表达。这一目标包括两个组成部分。首先,我们将确定
血管紧张素Ⅱ受体AT2R在RVLM中过度表达对动脉血压(AP)、心率(HR)、
清醒的正常大鼠和心力衰竭大鼠的心功能和去甲肾上腺素排泄。此外,水的摄入,
尿液排泄,并测量体重。第二,我们将观察其急性影响
RVLM内微量注射AT1R和AT2R激动剂和拮抗剂AT2R高表达
AP、HR和肾交感神经活动(RSNA)。我们还将探索细胞内的参与
AR2R信号转导交感抑制。这包括NO/cGMP和PLA2/AA/12-LO/PP2A通路。目标
2.研究AT2R过表达对大鼠单个交感神经元电活动的影响
麻醉大鼠的RVLm。我们将直接记录RVLM的细胞外单单位放电
AT2R过表达后的交感前神经元。目标3:确定
AT2R在RVLM交感前神经元钾电流上的过度表达。用人
膜片钳和脑干切片准备,我们将直接记录交感神经前膜的钾电流
AT2R过表达后的神经元。这些研究将有助于加深对
慢性心力衰竭时交感前神经元的血管紧张素信号转导。他们将强调
AT1和AT2受体信号在设定交感兴奋水平和识别中的平衡
可能成为CHF治疗的新靶点。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lie Gao其他文献
Lie Gao的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lie Gao', 18)}}的其他基金
Skeletal Muscle Nrf2: Exercise-Induced Cardiovascular Protection
骨骼肌 Nrf2:运动引起的心血管保护
- 批准号:
10545275 - 财政年份:2022
- 资助金额:
$ 34.99万 - 项目类别:
Skeletal Muscle Nrf2: Exercise-Induced Cardiovascular Protection
骨骼肌 Nrf2:运动引起的心血管保护
- 批准号:
10340045 - 财政年份:2022
- 资助金额:
$ 34.99万 - 项目类别:
AT2 Receptors in the RVLM: Regulation of Sympathetic Outflow in Heart Failure
RVLM 中的 AT2 受体:心力衰竭中交感神经流出的调节
- 批准号:
8645694 - 财政年份:2009
- 资助金额:
$ 34.99万 - 项目类别:
AT2 Receptors in the RVLM: Regulation of Sympathetic Outflow in Heart Failure
RVLM 中的 AT2 受体:心力衰竭中交感神经流出的调节
- 批准号:
7651073 - 财政年份:2009
- 资助金额:
$ 34.99万 - 项目类别:
AT2 Receptors in the RVLM: Regulation of Sympathetic Outflow in Heart Failure
RVLM 中的 AT2 受体:心力衰竭中交感神经流出的调节
- 批准号:
8050647 - 财政年份:2009
- 资助金额:
$ 34.99万 - 项目类别:
AT2 Receptors in the RVLM: Regulation of Sympathetic Outflow in Heart Failure
RVLM 中的 AT2 受体:心力衰竭中交感神经流出的调节
- 批准号:
7807167 - 财政年份:2009
- 资助金额:
$ 34.99万 - 项目类别:
相似海外基金
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
- 批准号:
MR/X02329X/1 - 财政年份:2024
- 资助金额:
$ 34.99万 - 项目类别:
Fellowship
Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
- 批准号:
MR/Y009568/1 - 财政年份:2024
- 资助金额:
$ 34.99万 - 项目类别:
Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
- 批准号:
10090332 - 财政年份:2024
- 资助金额:
$ 34.99万 - 项目类别:
Collaborative R&D
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
- 批准号:
MR/X021882/1 - 财政年份:2024
- 资助金额:
$ 34.99万 - 项目类别:
Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
- 批准号:
2312694 - 财政年份:2024
- 资助金额:
$ 34.99万 - 项目类别:
Standard Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
- 批准号:
EP/Y003527/1 - 财政年份:2024
- 资助金额:
$ 34.99万 - 项目类别:
Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
- 批准号:
EP/Y030338/1 - 财政年份:2024
- 资助金额:
$ 34.99万 - 项目类别:
Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
- 批准号:
MR/X029557/1 - 财政年份:2024
- 资助金额:
$ 34.99万 - 项目类别:
Research Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
- 批准号:
24K19395 - 财政年份:2024
- 资助金额:
$ 34.99万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Collaborative Research: Changes and Impact of Right Ventricle Viscoelasticity Under Acute Stress and Chronic Pulmonary Hypertension
合作研究:急性应激和慢性肺动脉高压下右心室粘弹性的变化和影响
- 批准号:
2244994 - 财政年份:2023
- 资助金额:
$ 34.99万 - 项目类别:
Standard Grant